We are excited to be involved in this pioneering subretinal implant technology and to announce the first patients implanted in the UK were successful. The visual results of these patients exceeded our expectations. This technology represents a genuinely exciting development and is an important step forward in our attempts to offer people with RP a better quality of life.
Robert MacLaren
ReplyDeleteProfessor of Ophthalmology at the University of Oxford and a consultant retinal surgeon at the Oxford Eye Hospital
Our clinical and laboratory research is dedicated to finding new treatments for blindness, particularly in patients with incurable retinal diseases. In addition to developing gene therapy with new adeno-associated viral (AAV) vectors in the laboratory, we are currently leading a gene therapy trial to treat choroideraemia. We are also developing treatments for other macular and retinal degenerations. We have a clinical research program in artifical vision with bio-genetic and electronic devices. In the clinic we are testing new imaging methods for retinal diseases and in the operating theatre we are developing new eye surgery techniques for age-related macular degeneration, cataract and macular hole surgery.
ReplyDelete